CCT3 CAR-T
EXUMA’s proprietary, centralized CCT3 CAR-T process is launch-ready and needs no further modifications to be commercially viable.
- A proprietary process which could support market entry
- 17-day vein-to-vein, fully closed, fresh in, frozen out process
- No manufacturing failures from IIT studies in China
- Uses real-time monitoring electronic batch record bar code system to help mitigate potential errors
rPOC SC CAR-TaNKs
rPOC subcutaneous (SC) technology could expand access to potentially life-saving CAR-based therapies while reducing costs by avoiding the need for adjuvant chemotherapy and extended hospital admissions.
- Subcutaneously injected CAR-TaNK product can be efficiently manufactured in less than six hours
- Potential for fewer side effects by eliminating lymphodepleting chemotherapy
- Leveraging a unique T- and NK-like (“TaNK”) cell population generated from the technology, with properties of both T and NK cells, rPOC SC may produce lower systemic cytokine burden during expansion, while maintaining durability of anti-tumor response
- Has potential for administration in a broader setting of care due to potential for reduced treatment-related complications
